These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10155582)

  • 1. The impact of recent legislative change in Germany.
    Münnich FE; Sullivan K
    Pharmacoeconomics; 1994; 6 Suppl 1():22-7. PubMed ID: 10155582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current issues in German healthcare.
    Graf von der Schulenburg JM; Uber A
    Pharmacoeconomics; 1997 Nov; 12(5):517-23. PubMed ID: 10174318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reimbursement and cost containment: a German perspective.
    Breyer F
    Pharmacoeconomics; 2002; 20 Suppl 3():87-94. PubMed ID: 12457429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnostics in light of massive changes in official health policies.
    Müller B
    Clin Chem; 1994 Aug; 40(8):1658-62. PubMed ID: 8045025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Market Concentration in the Statutory Health Insurance of Germany since the Introduction of Free Choice of Sickness Funds].
    Götze R
    Gesundheitswesen; 2016 Nov; 78(11):715-720. PubMed ID: 25760099
    [No Abstract]   [Full Text] [Related]  

  • 7. Consequences of implementing a drug budget for office-based physicians in Germany.
    Schöffski O
    Pharmacoeconomics; 1996; 10 Suppl 2():37-47. PubMed ID: 10163434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pricing and reimbursement of pharmaceuticals.
    Towse A
    Pharmacoeconomics; 1994; 6 Suppl 1():36-8. PubMed ID: 10155584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost containment: Europe. Germany.
    Burchardi H; Schuster HP; Zielmann S
    New Horiz; 1994 Aug; 2(3):364-74. PubMed ID: 8087598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
    Gress S; Niebuhr D; May U; Wasem J
    Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of the Health Structure Regulation on prescribing behavior of established physicians].
    Güther B
    Gesundheitswesen; 1995 Apr; 57(4):185-91. PubMed ID: 7787368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Health care structure legislation--reform of health insurance].
    Pick P
    Gesundheitswesen; 1993 Mar; 55(3):140-5. PubMed ID: 8471809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
    Henschke C; Sundmacher L; Busse R
    Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Price elasticities in the German Statutory Health Insurance market before and after the health care reform of 2009.
    Pendzialek JB; Danner M; Simic D; Stock S
    Health Policy; 2015 May; 119(5):654-63. PubMed ID: 25670009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A DRG based future hospital funding scheme: state of implementation and impact in the field of rehabilitation].
    Rochell B; Roeder N
    Rehabilitation (Stuttg); 2002 Feb; 41(1):1-9. PubMed ID: 11830787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteral nutrition reimbursement - the rationale for the policy: the German perspective.
    Pahne N
    Nestle Nutr Workshop Ser Clin Perform Programme; 2009; 12():71-78. PubMed ID: 19858687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
    Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
    Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging government requirement for economic evaluation of pharmaceuticals.
    Drummond M
    Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.